Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections

ABSTRACT

This invention relates to thieno[3,2-d]pyrimidines derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of Ser. No. 15/420,055 filed on Jan.30, 2017, which is a continuation of Ser. No. 14/908,237 filed on Jan.28, 2016, which is a national stage filing under USC 371 ofinternational application PCT/EP2014/066219 filed on Jul. 29, 2014,which claims priority to European Patent Application No. 13178534.7filed Jul. 30, 2013, the complete disclosures of which are herebyincorporated herein by reference for all purposes.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted electronically in ASCII format and is hereby incorporated byreference in its entirety. Said ASCII copy, created on May 7, 2019, isnamed 613045-NTT-301USCON2-SEQUENCE.TXT and is 611 bytes in size.

This invention relates to thieno[3,2-d]pyrimidine derivatives, processesfor their preparation, pharmaceutical compositions, and their use intreating viral infections.

The present invention relates to the use of thieno[3,2-d]pyrimidinederivatives in the treatment of viral infections, immune or inflammatorydisorders, whereby the modulation, or agonism, of toll-like-receptors(TLRs) is involved. Toll-Like Receptors are primary transmembraneproteins characterized by an extracellular leucine rich domain and acytoplasmic extension that contains a conserved region. The innateimmune system can recognize pathogen-associated molecular patterns viathese TLRs expressed on the cell surface of certain types of immunecells. Recognition of foreign pathogens activates the production ofcytokines and upregulation of co-stimulatory molecules on phagocytes.This leads to the modulation of T cell behaviour.

It has been estimated that most mammalian species have between ten andfifteen types of Toll-like receptors. Thirteen TLRs (named TLR1 toTLR13) have been identified in humans and mice together, and equivalentforms of many of these have been found in other mammalian species.However, equivalents of certain TLR found in humans are not present inall mammals. For example, a gene coding for a protein analogous to TLR10in humans is present in mice, but appears to have been damaged at somepoint in the past by a retrovirus. On the other hand, mice express TLRs11, 12, and 13, none of which are represented in humans. Other mammalsmay express TLRs which are not found in humans. Other non-mammalianspecies may have TLRs distinct from mammals, as demonstrated by TLR14,which is found in the Takifugu pufferfish. This may complicate theprocess of using experimental animals as models of human innateimmunity.

For reviews on TLRs see the following journal articles. Hoffmann, J. A.,Nature, 426, p 33-38, 2003; Akira, S., Takeda, K., and Kaisho, T.,Annual Rev. Immunology, 21, p 335-376, 2003; Ulevitch, R. J., NatureReviews: Immunology, 4, p 512-520, 2004.

Compounds indicating activity on Toll-Like receptors have beenpreviously described such as purine derivatives in WO 2006/117670,adenine derivatives in WO 98/01448 and WO 99/28321, and pyrimidines inWO 2009/067081.

However, there exists a strong need for novel Toll-Like receptormodulators having preferred selectivity, higher potency, and an improvedsafety profile compared to the compounds of the prior art.

In accordance with the present invention a compound of formula (I) isprovided

or a pharmaceutically acceptable salt, tautomer(s), stereo-isomericform, solvate or polymorph thereof, wherein

R₁ is selected from hydrogen, halogen, —CH₃ or —CF₃,

R₂ is selected from hydrogen, halogen, C₁₋₆ alkyl or C₃₋₆ cycloalkyl,

R₃ is C₁₋₈ alkyl optionally substituted by one or more substituentsindependently selected from aryl, aryloxy, halogen, hydroxyl,alkylamino, dialkylamino, C₁₋₆ alkenyl, C₁₋₆alkoxy, carboxylic acid,carboxylic ester, carboxylic amide, nitrile, sulfonamide, sulfamide,acyl sulfonamide, or

R₃ is an alkylaryl optionally substituted by one or more substituentsindependently selected from aryl, aryloxy, halogen, alkylamino,dialkylamino, C₁₋₆ alkyl, C₁₋₆ alkenyl, C₁₋₆ alkoxy, carboxylic acid,carboxylic ester, carboxylic amide, nitrile, sulfonamide, sulfamide, oracyl sulfonamide.

The compounds of formula (I) and their pharmaceutically acceptablesalts, tautomer(s), stereo-isomeric forms, solvate or polymorph thereofhave activity as pharmaceuticals, in particular as modulators ofToll-Like Receptors 7 and 8 (especially TLR 8).

In a further aspect the present invention provides a pharmaceuticalcomposition comprising a compound of formula (I) or a pharmaceuticallyacceptable salt, tautomer, stereo-isomeric form, solvate or polymorphthereof together with one or more pharmaceutically acceptableexcipients, diluents or carriers.

Furthermore a compound of formula (I) or a pharmaceutically acceptablesalt, solvate, tautomer, stereo-isomeric form or polymorph thereofaccording to the current invention, or a pharmaceutical compositioncomprising said compound of formula (I) or a pharmaceutically acceptablesalt, solvate, tautomer, stereo-isomeric form or polymorph thereof canbe used as a medicament.

Another aspect of the invention is that a compound of formula (I) or itspharmaceutically acceptable salt, solvate, tautomer, stereo-isomericform or polymorph thereof, or said pharmaceutical composition comprisingsaid compound of formula (I) or a pharmaceutically acceptable salt,solvate, tautomer, stereo-isomeric form or polymorph thereof can be usedaccordingly in the treatment of a disorder in which the modulation ofTLR7 and/or TLR8 is involved preferably TLR8.

The term “(C₁₋₈)-alkyl” and “(C₁₋₆)-alkyl” refers to a straight-chain,branched-chain or cyclic saturated aliphatic hydrocarbon containing thespecified number of carbon atoms.

The term “halogen” refers to fluorine, chlorine, bromine or iodine.

The term “alkylaryl” refers to a straight-chain or branched-chainsaturated aliphatic hydrocarbon containing the specified number ofcarbon atoms substituted by an aryl wherein “aryl” is defined as below.

The term “alkenyl” refers to an alkyl as defined above consisting of atleast two carbon atoms and at least one carbon-carbon double bond.

The term “cycloalkyl” refers to a carbocyclic ring containing thespecified number of carbon atoms.

The term “alkoxy” refers to an alkyl (carbon and hydrogen chain) groupsingular bonded to oxygen like for instance a methoxy group or ethoxygroup.

The term “aryl” means an aromatic ring structure optionally comprisingone or two heteroatoms selected from N, O and S, in particular from Nand O. Said aromatic ring structure may have 5, 6 or 7 ring atoms. Inparticular, said aromatic ring structure may have 5 or 6 ring atoms.

The term “aryloxy” refers to an aromatic ring structure. Said aromaticgroup is singularly bonded to oxygen.

As used herein, any chemical formula with bonds shown only as solidlines and not as solid wedged or hashed wedged bonds, or otherwiseindicated as having a particular configuration (e.g. R, S) around one ormore atoms, contemplates each possible stereoisomer, or mixture of twoor more stereoisomers.

The terms “stereoisomers”, “stereoisomeric forms” or “stereochemicallyisomeric forms” hereinbefore or hereinafter are used interchangeably.

The invention includes all stereoisomers of the compounds of theinvention either as a pure stereoisomer or as a mixture of two or morestereoisomers.

Enantiomers are stereoisomers that are non-superimposable mirror imagesof each other.

A 1:1 mixture of a pair of enantiomers is a racemate or racemic mixture.

Diastereomers (or diastereoisomers) are stereoisomers that are notenantiomers, i.e. they are not related as mirror images. If a compoundcontains a double bond, the substituents may be in the E or the Zconfiguration. If a compound contains an at least disubstitutednon-aromatic cyclic group, the substituents may be in the cis or transconfiguration.

Therefore, the invention includes enantiomers, diastereomers, racemates,E isomers, Z isomers, cis isomers, trans isomers and mixtures thereof,whenever chemically possible.

The meaning of all those terms, i.e. enantiomers, diastereomers,racemates, E isomers, Z isomers, cis isomers, trans isomers and mixturesthereof are known to the skilled person.

The absolute configuration is specified according to theCahn-Ingold-Prelog system. The configuration at an asymmetric atom isspecified by either R or S. Resolved stereoisomers whose absoluteconfiguration is not known can be designated by (+) or (−) depending onthe direction in which they rotate plane polarized light. For instance,resolved enantiomers whose absolute configuration is not known can bedesignated by (+) or (−) depending on the direction in which they rotateplane polarized light.

When a specific stereoisomer is identified, this means that saidstereoisomer is substantially free, i.e. associated with less than 50%,preferably less than 20%, more preferably less than 10%, even morepreferably less than 5%, in particular less than 2% and most preferablyless than 1%, of the other stereoisomers. Thus, when a compound ofFormula (I) is for instance specified as (R), this means that thecompound is substantially free of the (S) isomer; when a compound ofFormula (I) is for instance specified as E, this means that the compoundis substantially free of the Z isomer; when a compound of Formula (I) isfor instance specified as cis, this means that the compound issubstantially free of the trans isomer.

Pharmaceutically acceptable salts of the compounds of formula (I)include the acid addition and base salts thereof. Suitable acid additionsalts are formed from acids which form non-toxic salts. Suitable basesalts are formed from bases which form non-toxic salts.

The compounds of the invention may also exist in unsolvated and solvatedforms. The term “solvate” is used herein to describe a molecular complexcomprising the compound of the invention and one or morepharmaceutically acceptable solvent molecules, for example, ethanol.

The term “polymorph” refers to the ability of the compound of theinvention to exist in more than one form or crystal structure.

The compounds of the present invention may be administered ascrystalline or amorphous products. They may be obtained for example assolid plugs, powders, or films by methods such as precipitation,crystallization, freeze drying, spray drying, or evaporative drying.They may be administered alone or in combination with one or more othercompounds of the invention or in combination with one or more otherdrugs. Generally, they will be administered as a formulation inassociation with one or more pharmaceutically acceptable excipients. Theterm “excipient” is used herein to describe any ingredient other thanthe compound(s) of the invention. The choice of excipient dependslargely on factors such as the particular mode of administration, theeffect of the excipient on solubility and stability, and the nature ofthe dosage form.

The compounds of the present invention or any subgroup thereof may beformulated into various pharmaceutical forms for administrationpurposes. As appropriate compositions there may be cited allcompositions usually employed for systemically administering drugs. Toprepare the pharmaceutical compositions of this invention, an effectiveamount of the particular compound, optionally in addition salt form, asthe active ingredient is combined in intimate admixture with apharmaceutically acceptable carrier, which carrier may take a widevariety of forms depending on the form of preparation desired foradministration. These pharmaceutical compositions are desirably inunitary dosage form suitable, for example, for oral, rectal, orpercutaneous administration. For example, in preparing the compositionsin oral dosage form, any of the usual pharmaceutical media may beemployed such as, for example, water, glycols, oils, alcohols and thelike in the case of oral liquid preparations such as suspensions,syrups, elixirs, emulsions, and solutions; or solid carriers such asstarches, sugars, kaolin, diluents, lubricants, binders, disintegratingagents and the like in the case of powders, pills, capsules, andtablets. Because of their ease in administration, tablets and capsulesrepresent the most advantageous oral dosage unit forms, in which casesolid pharmaceutical carriers are obviously employed. Also included aresolid form preparations that can be converted, shortly before use, toliquid forms. In the compositions suitable for percutaneousadministration, the carrier optionally comprises a penetration enhancingagent and/or a suitable wetting agent, optionally combined with suitableadditives of any nature in minor proportions, which additives do notintroduce a significant deleterious effect on the skin. Said additivesmay facilitate the administration to the skin and/or may be helpful forpreparing the desired compositions. These compositions may beadministered in various ways, e.g., as a transdermal patch, as aspot-on, as an ointment. The compounds of the present invention may alsobe administered via inhalation or insufflation by means of methods andformulations employed in the art for administration via this way. Thus,in general the compounds of the present invention may be administered tothe lungs in the form of a solution, a suspension or a dry powder.

It is especially advantageous to formulate the aforementionedpharmaceutical compositions in unit dosage form for ease ofadministration and uniformity of dosage. Unit dosage form as used hereinrefers to physically discrete units suitable as unitary dosages, eachunit containing a predetermined quantity of active ingredient calculatedto produce the desired therapeutic effect in association with therequired pharmaceutical carrier. Examples of such unit dosage forms aretablets (including scored or coated tablets), capsules, pills, powderpackets, wafers, suppositories, injectable solutions or suspensions andthe like, and segregated multiples thereof.

Those of skill in the treatment of infectious diseases will be able todetermine the effective amount from the test results presentedhereinafter. In general it is contemplated that an effective dailyamount would be from 0.01 mg/kg to 50 mg/kg body weight, more preferablyfrom 0.1 mg/kg to 10 mg/kg body weight. It may be appropriate toadminister the required dose as two, three, four or more sub-doses atappropriate intervals throughout the day. Said sub-doses may beformulated as unit dosage forms, for example, containing 1 to 1000 mg,and in particular 5 to 200 mg of active ingredient per unit dosage form.

The exact dosage and frequency of administration depends on theparticular compound of formula (I) used, the particular condition beingtreated, the severity of the condition being treated, the age, weightand general physical condition of the particular patient as well asother medication the individual may be taking, as is well known to thoseskilled in the art. Furthermore, it is evident that the effective amountmay be lowered or increased depending on the response of the treatedsubject and/or depending on the evaluation of the physician prescribingthe compounds of the instant invention. The effective amount rangesmentioned above are therefore only guidelines and are not intended tolimit the scope or use of the invention to any extent.

PREPARATION OF COMPOUNDS OF FORMULA (I)

Overall Scheme.

The preparation of compounds of type I are described in the literature(Synthetic Communications, 9(8), p 731-4, 1979; SyntheticCommunications, 32(16), 2565-2568; 2002).3-aminothiophene-2-carboxylates are mixed with cyanamide in a polarsolvent (e.g. ethanol) containing acid (e.g. HCl) to form intermediatesII with heat as described in the literature (Synthesis, (9), p 1428,2010). Intermediate II in polar, aprotic solvent can be mixed with BOPor PyBOP in combination with a base (e.g. DBU) and the amine to lead tothe formation of final products (III) at room temperature.Alternatively, the alcohol in intermediates of type II can be convertedto chlorine using described methods and chlorinating agents, such asPOCl₃, often with heat and in the presence of solvent, and optionallywith base. After isolation, the 4-chloro intermediate can then be usedto form products of type III by heating with the amine in base and polarsolvent (e.g. acetonitrile).

Preparation of 1

Into a 50 mL glass vial was placed B (500 mg, 2.76 mmol), anhydrous DMF(5 mL), DBU (1.26 g, 8.28 mmol), n-butylamine (605 mg, 8.3 mmol), andBOP (1.46 g, 3.31 mmol). The vial was sealed and shaken for 16 hours atroom temperature. LC-MS showed conversion to product. The crude reactionmixture was purified by preparatory HPLC (RP SunFire Prep C18 OBD-10 μm,30×150 mm, mobile phase 0.25% aq. ammonium carbonate, to acetonitrile).The best fractions were pooled and the solvents were removed underreduced pressure to afford a white solid, 1. LC-MS m/z=237 (M+H).

TABLE 1 Compounds of formula (I) and corresponding analytical data.Compounds were prepared according to the methods described in theexperimental section. LC LC-MS Mass Method, Found # STRUCTURE ¹H NMR Rt(min) (M + H) 1

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.91 (t, J = 7.4 Hz, 3 H), 1.33 (dq, J =14.9, 7.4 Hz, 2 H), 1.49- 1.61 (m, 2 H), 3.35 (s, 3 H), 3.36- 3.42 (m, 2H), 5.74 (s, 2 H), 6.69 (s, 1 H), 7.03 (t, J = 5.5 Hz, 1 H) A, 0.8  2372

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.91 (t, J = 7.4 Hz, 3 H), 1.26- 1.42(m, 2 H), 1.48-1.62 (m, 2 H), 2.17 (d, J = 1.1 Hz, 3 H), 3.37- 3.46 (m,2 H), 5.83 (s, 2 H), 7.14 (s, 1 H), 7.43 (d, J = 1.1 Hz, 1 H) B, 1.52237 3

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.90 (t, J = 7.4 Hz, 3 H), 1.27- 1.35(m, 2 H), 1.36 (s, 9 H), 1.47- 1.60 (m, 2 H), 3.35-3.43 (m, 2 H), 5.72(s, 2 H), 6.73 (s, 1 H), 7.04 (t, J = 5.5 Hz, 1 H) B, 1.83 279 4

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.85 (br. s., 3 H), 1.17-1.39 (m, 4 H),1.43-1.56 (m, 1 H), 1.65 (br. s., 1 H), 3.39-3.54 (m, 2 H), 4.26 (d, J =4.4 Hz, 1 H), 4.65 (br. s., 1 H), 5.75 (s, 2 H), 6.84 (d, J = 8.4 Hz, 1H), 6.95 (d, J = 5.3 Hz, 1 H), 7.81 (d, J = 5.3 Hz, 1 H) A, 0.70 267 5

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.78-0.94 (m, 3 H), 1.16- 1.41 (m, 2 H),1.45-1.69 (m, 2 H), 3.47-3.53 (m, 1 H), 4.30- 4.47 (m, 2 H), 7.18-7.28(m, 1 H), 7.77 (br. s., 2 H), 8.18 (d, J = 5.3 Hz, 1 H), 8.92 (d, J =8.4 Hz, 1 H), 13.26 (br. s., 1 H) A, 0.63 253 6

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.84 (br. s., 3 H), 1.19-1.39 (m, 4 H),1.42-1.57 (m, 1 H), 1.65 (br. s., 1 H), 3.37-3.55 (m, 2 H), 3.71-4.21(m, 1 H), 4.28 (d, J = 4.6 Hz, 1 H), 5.97 (br. s., 2 H), 6.97 (d, J =5.3 Hz, 1 H), 7.05 (d, J = 8.4 Hz, 1 H), 7.84 (d, J = 5.3 Hz, 1 H) A,0.70 267 7

¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 0.98 (t, J = 7.4 Hz, 3 H),1.39-1.51 (m, 2 H), 1.61-1.69 (m, 2 H), 1.74 (s, 1 H), 3.59 (td, J =7.2, 5.7 Hz, 2 H), 4.71 (br. s., 2 H), 7.11 (d, J = 5.3 Hz, 1 H), 7.56(d, J = 5.3 Hz, 1 H) B, 0.71 223 8

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.81-0.93 (m, 3 H), 1.20- 1.40 (m, 4 H),1.52-1.65 (m, 2 H), 1.74 (q, J = 6.6 Hz, 2 H), 3.40-3.50 (m, 2 H),4.38-4.52 (m, 2 H), 7.22 (d, J = 5.5 Hz, 1 H), 7.63-7.82 (m, 2 H), 8.18(d, J = 5.5 Hz, 1 H), 8.82 (d, J = 8.4 Hz, 1 H) A, 0.76 281 9

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.89 (t, J = 7.3 Hz, 3 H), 1.16 (d, J =6.6 Hz, 3H), 1.26-1.38 (m, 2 H), 1.39-1.51 (m, 1 H), 1.53- 1.64 (m, 1H), 4.28-4.39 (m, 1 H), 5.77 (s, 2 H), 6.95 (d, J = 5.3 Hz, 1 H), 7.01(d, J = 8.4 Hz, 1 H), 7.81 (d, J = 5.3 Hz, 1 H) A, 0.82 237 10

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.84-0.98 (m, 3 H), 1.27- 1.51 (m, 2 H),1.57-1.70 (m, 1 H), 1.80-1.98 (m, 1 H), 3.69 (s, 3 H), 4.76-4.92 (m, 1H), 7.27 (d, J = 5.3 Hz, 1 H), 7.89 (br. s., 2 H), 8.26 (d, J = 5.3 Hz,1 H), 9.47 (d, J = 7.3 Hz, 1 H) A, 0.76 281 11

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.87 (t, J = 6.9 Hz, 3 H), 1.25- 1.37(m, 4 H), 1.57 (br. s., 2 H), 3.39-3.44 (m, 2 H), 5.80 (s, 2 H), 6.95(d, J = 5.3 Hz, 1 H), 7.25 (s, 1 H), 7.80 (d, J = 5.3 Hz, 1 H) A, 0.84237 12

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.88 (t, J = 7.3 Hz, 3 H), 1.21- 1.43(m, 2 H), 1.50 (dtd, J = 13.5, 9.0, 9.0, 5.0 Hz, 1 H), 1.57-1.69 (m, 1H), 3.38-3.53 (m, 2 H), 4.29 (d, J = 4.6 Hz, 1 H), 4.62 (br. s., 1 H),5.80 (s, 2 H), 6.87 (d, J = 8.4 Hz, 1 H), 6.96 (d, J = 5.3 Hz, 1 H),7.82 (d, J = 5.3 Hz, 1 H) A, 0.61 253.1 13

¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 0.95 (t, J = 7.3 Hz, 3 H),1.32-1.50 (m, 2 H), 1.51-1.71 (m, 2H), 2.31 (d, J = 1.1 Hz, 3H), 3.34(s, 1 H), 3.67 (dd, J = 11.0, 6.4 Hz, 1 H), 3.83 (dd, J = 11.0, 3.3 Hz,1 H), 4.19-4.38 (m, 1 H), 4.77 (d, J = 7.3 Hz, 1 H), 4.87 (s, 2 H), 7.19(d, J = 1.1 Hz, 1 H) A, 0.67 267.1 14

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.80-0.94 (m, 3 H), 1.20- 1.39 (m, 4 H),1.49-1.64 (m, 2 H), 2.17 (d, J = 1.1 Hz, 3 H), 3.36- 3.43 (m, 2 H), 5.82(s, 2 H), 7.15 (t, J = 5.5 Hz, 1 H), 7.43 (d, J = 1.1 Hz, 1 H) B, 1.69251.0 15

¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 0.96 (t, J = 7.4 Hz, 3H), 1.22-1.33(m, 1 H), 1.35-1.52 (m, 1 H), 1.74- 1.86 (m, 1 H), 1.87-2.01 (m, 1 H),2.33 (d, J = 1.1 Hz, 3H), 3.76 (s, 3 H), 4.75 (br. s., 2 H), 4.97 (td, J= 7.5, 5.6 Hz, 1 H), 5.10 (d, J = 7.7 Hz, 1 H), 7.22 (d, J = 1.1 Hz, 1H) E, 1.02 295.2 16

¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 0.92 (t, J = 7.4 Hz, 3H), 1.26-1.50(m, 3 H), 1.51-1.66 (m, 2 H), 1.68- 1.79 (m, 1 H), 1.86-2.03 (m, 1 H),2.32 (d, J = 1.1 Hz, 3 H), 3.45-3.68 (m, 2 H), 4.41 (ddd, J = 11.1, 5.4,2.9 Hz, 1 H), 4.52 (d, J = 8.8 Hz, 1 H), 4.97 (s, 2 H), 7.20 (d, J = 1.1Hz, 1 H) A, 0.72 281.2 17

B, 1.38 281.1 18

1H NMR (400 MHz, DMSO-d6) δ ppm 0.85 (t, J = 6.5 Hz, 3 H), 1.11-1.35 (m,4 H), 1.38-1.56 (m, 1 H), 1.57-1.74 (m, 1 H), 2.18 (d, J = 0.9 Hz, 3 H),3.39-3.55 (m, 2 H), 4.19-4.35 (m, 1 H), 4.66 (br. s., 1 H), 5.79 (s, 2H), 6.75 (d, J = 8.4 Hz, 1 H), 7.44 (d, J = 1.1 Hz, 1 H) B, 1.41 281.119

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.76-0.91 (m, 3 H), 1.16- 1.36 (m, 4 H),1.44-1.58 (m, 2 H), 1.59-1.79 (m, 2 H), 2.17 (d, J = 1.1 Hz, 3 H),3.38-3.49 (m, 2 H), 4.34 (d, J = 7.5 Hz, 1 H), 4.40 (t, J = 5.4 Hz, 1H), 5.83 (s, 2 H), 6.87 (d, J = 8.6 Hz, 1 H), 7.44 (d, J = 1.1 Hz, 1 H)B, 1.49 295.1 20

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.88 (t, J = 7.3 Hz, 3 H), 1.18 (d, J =6.5 Hz, 3 H), 1.23-1.38 (m, 2 H), 1.40-1.69 (m, 2 H), 2.58 (s, 3 H),4.25-4.45 (m, 1 H), 6.93 (s, 1 H), 7.50 (br. s., 2 H), 8.50 (br. s., 1H) B, 1.66 251.1 21

¹H NMR (400 MHz, DMSO-d₆) □ ppm 0.85 (t, J = 6.5 Hz, 3 H), 1.17- 1.40(m, 4 H), 1.43-1.71 (m, 2 H), 2.59 (s, 3 H), 3.45-3.50 (m, 2 H),4.20-4.41 (m, 1 H), 6.99 (d, J = 0.8 Hz, 1 H), 7.66 (br. s., 2 H), 8.71(d, J = 8.5 Hz, 1 H), 13.00 (br. s., 1 H) D, 2.49 281.1 22

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.85 (t, J = 6.7 Hz, 3 H), 1.08- 1.38(m, 4 H), 1.43-1.71 (m, 2 H), 2.52 (br. s., 2 H), 2.57 (m, J = 1.0 Hz, 3H), 4.29 (d, J = 5.0 Hz, 1 H), 4.82 (br. s., 1 H), 6.92 (d, J = 1.3 Hz,1 H), 7.20 (br. s., 2H), 8.22 (br. s., 1 H) D, 2.67 281.1 23

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.85 (t, J = 6.8 Hz, 3 H), 1.16- 1.35(m, 4 H), 1.40 (s, 9 H), 1.51 (dd, J = 9.0, 4.8 Hz, 1 H), 1.64 (d, J =6.0 Hz, 1 H), 3.47 (br. s., 2 H), 4.33 (d, J = 4.8 Hz, 1 H), 4.83 (br.s., 1 H), 7.00 (s, 1 H), 7.67 (br. s., 2 H), 8.66 (d, J = 8.5 Hz, 1 H)C, 2.67 323.1

Analytical Methods

General information: the LC measurement was performed using an AcquityUPLC (Waters) system comprising a binary pump, a sample organizer, acolumn heater (set at 55° C.), a diode-array detector (DAD) and a columnas specified in the respective methods below. Flow from the column wassplit to a MS spectrometer. The MS detector was configured with anelectrospray ionization source. Mass spectra were acquired by scanningfrom 100 to 1000 in 0.18 seconds using a dwell time of 0.02 seconds. Thecapillary needle voltage was 3.5 kV and the source temperature wasmaintained at 140° C. Nitrogen was used as the nebulizer gas.

LC-MS Methods.

LC-MS Flow Run Method (mL/min)/ time code Column Mobile phase GradientTemp (° C.) (min) A Waters:BEH C18 A: 10 mM From 95% A to 0.8/55 2 (1.7μm, 2.1 × 50 mm) CH₃COONH₄ in 5% A in 1.3 min, 95% H₂O + 5% held for 0.7min. CH₃CNB: CH₃CN B Waters:HSS T3 A: 10 mM From 100% A to 0.8/55 3.5(1.8 μm, 2.1 × 100 mm) CH₃COONH₄ in 5% A in 2.10 min, 95% H₂O + 5% to 0%A in 0.90 CH₃CN min, to 5% A in B: CH₃CN 0.5 min C Agilent:TC-C18 A:CF₃COOH 0.1% 100% A for 1 min, 0.8/50 10.5 (5 μm, 2.1 × 50 mm) in water,B: to 40% A in 4 min, CF₃COOH 0.05% to 15% A in in CH₃CN 2.5 min, to100% A in 2 min D Agilent:TC-C18 A: CF₃COOH 0.1% 90% A for 0.8/50 10.5(5 μm, 2.1 × 50 mm) in water, B: 0.8 min, to 20% A CF₃COOH 0.05% in 3.7min, held in CH₃CN for 3 min, back to 90% A in 2 min. E Waters:BEH C18A: 10 mM From 95% A to 0.7/70 1.8 (1.7 μm, 2.1*50 mm) CH₃COONH₄ in 5% Ain 1.3 min, 90% H₂O + 10% held for 0.2 min, CH₃CN to 95% A in B: MeOH0.2 min held for 0.1 min.

Biological Activity of Compounds of Formula (I)

Description of Biological Assays

Assessment of TLR7 and TLR8 Activity

The ability of compounds to activate human TLR7 and/or TLR8 was assessedin a cellular reporter assay using HEK293 cells transiently transfectedwith a TLR7 or TLR8 expression vector and NFκB-luc reporter construct.

Briefly, HEK293 cells were grown in culture medium (DMEM supplementedwith 10% FCS and 2 mM Glutamine). For transfection of cells in 15 cmdishes, cells were detached with Trypsin-EDTA, transfected with a mix ofCMV-TLR7 or TLR8 plasmid (1700 ng), NFκB-luc plasmid (850 ng) and atransfection reagent and incubated for 48 h at 37° C. in a humidified 5%CO₂ atmosphere. Transfected cells were then washed in PBS, detached withTrypsin-EDTA and resuspended in medium to a density of 1.25×10⁵cells/mL. Forty microliters of cells were then dispensed into each wellin 384-well plates, where 200 nL of compound in 100% DMSO was alreadypresent. Following 6 hours incubation at 37° C., 5% CO₂, the luciferaseactivity was determined by adding 15 μL of Steady Lite Plus substrate(Perkin Elmer) to each well and readout performed on a ViewLux ultraHTSmicroplate imager (Perkin Elmer). Dose response curves were generatedfrom measurements performed in quadruplicates. Lowest effectiveconcentrations (LEC) values, defined as the concentration that inducesan effect which is at least two fold above the standard deviation of theassay, were determined for each compound.

Compound toxicity was determined in parallel using a similar dilutionseries of compound with 40 μL per well of cells transfected with theCMV-TLR7 construct alone (1.25×10⁵ cells/mL), in 384-well plates. Cellviability was measured after 6 hours incubation at 37° C., 5% CO₂ byadding 15 μL of ATP lite (Perkin Elmer) per well and reading on aViewLux ultraHTS microplate imager (Perkin Elmer). Data was reported asCC₅₀.

In parallel, a similar dilution series of compound was used (200 nL ofcompound in 100% DMSO) with 40 μL per well of cells transfected withNFκB-luc reporter construct alone (1.25×10⁵ cells/mL). Six hours afterincubation at 37° C., 5% CO₂, the luciferase activity was determined byadding 15 μl of Steady Lite Plus substrate (Perkin Elmer) to each welland readout performed on a ViewLux ultraHTS microplate imager (PerkinElmer). Counterscreen data is reported as LEC.

Activation of ISRE Promoter Elements

The potential of compounds to induce IFN-I was also evaluated bymeasuring the activation of interferon-stimulated responsive elements(ISRE) by conditioned media from PBMC. The ISRE element of sequenceGAAACTGAAACT (SEQ ID NO: 1) is highly responsive to the STAT1-STAT2-IRF9transcription factor, activated upon binding of IFN-I to their receptorIFNAR (Clontech, PT3372-5W). The plasmid pISRE-Luc from Clontech (ref.631913) contains 5 copies of this ISRE element, followed by the fireflyluciferase ORF. A HEK293 cell line stably transfected with pISRE-Luc(HEK-ISREluc) was established to profile the conditioned PBMC cellculture media.

Briefly, PBMCs were prepared from buffy coats of at least two donorsusing a standard Ficoll centrifugation protocol. Isolated PBMCs wereresuspended in RPMI medium supplemented with 10% human AB serum and2×10⁵ cells/well were dispensed into 384-well plates containingcompounds (70 μL total volume). After overnight incubation, 10 μL ofsupernatant was transferred to 384-well plates containing 5×10³HEK-ISREluc cells/well in 30 μL (plated the day before). Following 24hours of incubation, activation of the ISRE elements was measured byassaying luciferase activity using 40 μL/well Steady Lite Plus substrate(Perkin Elmer) and measured with ViewLux ultraHTS microplate imager(Perkin Elmer). The stimulating activity of each compound on theHEK-ISREluc cells was reported as LEC value, defined as the compoundconcentration applied to the PBMCs resulting in a luciferase activity atleast two fold above the standard deviation of the assay. The LEC inturn indicates the degree of ISRE activation on transfer of a definedamount of PBMC culture medium. Recombinant interferon α-2a (Roferon-A)was used as a standard control compound.

TABLE 2 Biological Activity of compounds of formula (I). Human TLR 7Human TLR 8 HEK-ISRE # (LEC) μM (LEC) μM luc (LEC) μM 1 1.0 0.5 0.1 22.2 1.0 0.6 3 1.2 1.2 0.4 4 0.5 0.03 0.04 5 2.7 0.2 0.4 6 >25 0.5 0.6 71.1 0.7 0.3 8 1.2 0.7 0.3 9 3.3 2.5 3.8 10 6.1 2.7 0.8 11 2.1 3.9 1.212 >25 7.2 21 13 12 0.2 0.6 14 6.8 1.9 3.2 15 >25 3.5 2.6 16 5.2 1.6 0.717 3.7 0.3 0.4 18 >25 0.8 1.7 19 3.9 1.6 0.6 20 >25 6.9 10.1 21 10.4 0.6— 22 2.9 0.2 — 23 2.7 2.6 —

All compounds showed no activity (LEC>25 μM) in the HEK 293 NF-kBcounterscreen assay described above.

1. A compound of formula (I)

or a pharmaceutically acceptable salt, tautomer(s), stereo-isomericform, or solvate thereof, wherein R₁ is selected from hydrogen, R₂ isselected from hydrogen, R₃ is C₁₋₈ alkyl optionally substituted byhydroxyl.
 2. (canceled)
 3. A compound according to claim 1, wherein thecompound is selected from the group consisting of:


4. A pharmaceutical composition comprising a compound of formula (I) ora pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms,or solvate thereof according to claim 1 together with one or morepharmaceutically acceptable excipients, diluents or carriers. 5.(canceled)
 6. A method of treating a disorder in which the modulation ofTLR7 and/or TLR8 is involved in a subject in need thereof, the methodcomprising administering to the subject a therapeutically effectiveamount of at least one compound of claim
 1. 7. The method of claim 6,wherein the disorder is a viral infection.